NasdaqCM - Nasdaq Real Time Price USD

KALA BIO, Inc. (KALA)

6.24 +0.05 (+0.81%)
As of 12:43 PM EDT. Market Open.

Key Executives

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Mark T. Iwicki Chairman & CEO 1.1M -- 1966
Mr. Todd Bazemore President & COO 783.04k -- 1970
Dr. Kim Brazzell Ph.D. Head of R&D and Chief Medical Officer 750.91k -- 1953
Dr. Justin Hanes Ph.D. Founder & Chair of the Scientific Advisory Board -- -- --
Ms. Mary Reumuth CPA CFO & Treasurer -- -- 1975
Ms. Jill S. Steier Executive Director of Investor Relations & Corporate Communications -- -- --
Mr. Eric L. Trachtenberg Chief Legal Officer, Chief Compliance Officer & Corporate Secretary 646.56k -- 1973
Mr. Vincent Kosewski Senior VP of Manufacturing & Supply Chain Management -- -- 1963
Mr. Darius Kharabi J.D., M.B.A. Chief Business Officer -- -- 1980
Dr. Francis S. Mah M.D. Chief Medical Advisor -- -- --

KALA BIO, Inc.

1167 Massachusetts Avenue
Arlington, MA 02476
United States
781 996 5252 https://www.kalarx.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
43

Description

KALA BIO, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of eye diseases. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.

Corporate Governance

KALA BIO, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

May 07, 2024 - May 13, 2024
KALA BIO, Inc. Earnings Call

Related Tickers

ATNF 180 Life Sciences Corp.
1.8400
+6.36%
 
CING Cingulate Inc.
0.8520
-1.54%
 
NRBO NeuroBo Pharmaceuticals, Inc.
3.0550
-0.16%
 
IMRN Immuron Limited
2.6400
+6.02%
 
PALI Palisade Bio, Inc.
6.19
-0.64%
 
GLMD Galmed Pharmaceuticals Ltd.
0.3869
-0.31%
 
SPRO Spero Therapeutics, Inc.
1.4850
+3.85%
 
LVTX LAVA Therapeutics N.V.
2.8199
+6.81%
 
FWBI First Wave BioPharma, Inc.
2.6849
-1.66%
 
CALC CalciMedica, Inc.
5.54
+1.51%